1. Ulusoy S. 1986’dan 2010’a Kinolonlar. ANKEM Derg 2010;24:96-100.
2. Hooper DC. Fluoroquinolones..https://www.uptodate.com/contents/fluoroquinolones?search=quinolones&source=search_result&selectedTitle=2%7E143&usage_type=default&display_
rank=1. Son erişim 30.03.2024.
3. Brar KR. Fluoroquinolone antibiotics: An overview.Adesh University Journal of Medical Sciences & Research 2020:26-30.
4. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22(8):438-45
5. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6:629-640.
6. Tam VH, Louie A, Fritsche TR, et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect
Dis 2007; 195:1818.
7. Jacoby, G. Cattoir V, D Hooper D, et al. qnr gene nomenclature. Antimicrob. Agents Chemother.2008;52:2297–2299.
8. Danilchanka O, Pavelnok M, Niederweis M, et al. Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrob. Agents Chemother. 2008;52:3127–3134
9. Hooper DC, Strahilevitz J. Quinolones. In: Bennett JF, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and practices of Infectious Diseases. 9th edition.Philadelphia, Else-
vier; 2020.
10. Ott SR, Allewelt M, Lorenz J, et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36:23.
11. Sillerström E, Wahlund E, Nord CE. In vitro activity of ABT-492 against anaerobic bacteria. J Chemother 2004; 16:227.
12. García MT, Pelaz C, Giménez MJ, et al. In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of
charcoal on susceptibility test results. Antimicrob Agents Chemother. 2000;44:2176–2178.
13. Gagliotti C, Buttazzi R, Sforza S, et al. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J
Infect. 2008;57:179–184.
14. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area
with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34:1165–1169.
15. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious
diseases society of America and the European society for microbiology and infectious diseases. Clin Infect Dis. 2011;52:103–120.
16. Christiano AP, Hollowell CMP, Kim H, et al. Double-blind randomized comparison of single-dose ciprofloxacin versus intravenous cefazolin in patients undergoing outpatient endourologic
surgery. Urology. 2000;55:182–185.
17. Anzueto A, Miravitlles M. Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respir Med. 2010;104:1396–1403.
18. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med.
2008;36:737–744.
19. Jackson MA, Schutze GE, et al. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.
20. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007; 26:879.
21. Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones–a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009; 143:75.
22. Acar S, Keskin-Arslan E, Erol-Coskun H, et al. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. Reprod
Toxicol 2019; 85:65.
23. Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9:517.
24. Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled
trials. Int J Antimicrob Agents 2018; 52:529.
25. Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 2014; 83:1261.
26. Sheikh S, Alvi U, Soliven B, Rezania K. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med 2021; 10.
27. Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. Drug Saf. 2019; 42:529.
28. Ball P, Mandell L, Patou G, et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents. 2004;23:421–429.
29. Schaad UB, Wedgwood J. Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother. 1992;30:414–416.
30. Wise BL, Peloquin C, Choi H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med. 2012;125:1228.
31. Hori S, Shimada J, Saito A, et al. Comparison of the inhibitory effect of new quinolones on gamma-aminobutyric acid receptor binding in the presence of anti inflammatory drugs. Rev Infect
Dis. 1989;11:1397–1398.